Free Trial
NASDAQ:GALT

Galectin Therapeutics Q4 2023 Earnings Report

Galectin Therapeutics logo
$4.15 +0.31 (+8.07%)
Closing price 04:00 PM Eastern
Extended Trading
$4.28 +0.13 (+3.13%)
As of 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galectin Therapeutics EPS Results

Actual EPS
-$0.16
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Galectin Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Galectin Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Friday, March 29, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Galectin Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Galectin Therapeutics Earnings Headlines

Galectin Therapeutics Inc. (GALT) - Yahoo Finance
Sell this, buy that
What you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strategy: Sell This, Buy That. In his newest presentation, Eric reveals 7 new trade ideas—pairing overhyped, vulnerable stocks with lesser-known opportunities showing real upside. These contrarian picks come from the same approach that helped him beat Wall Street legends 10-to-1 in Portfolios with Purpose.
Galectin Therapeutics Inc.
See More Galectin Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galectin Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galectin Therapeutics and other key companies, straight to your email.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ:GALT), a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

View Galectin Therapeutics Profile

More Earnings Resources from MarketBeat